<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305070</url>
  </required_header>
  <id_info>
    <org_study_id>FAIR 3.0</org_study_id>
    <nct_id>NCT01305070</nct_id>
  </id_info>
  <brief_title>Standard Balloon Angioplasty Versus Angioplasty With a Paclitaxel-eluting Balloon for Femoral Artery In-stent Restenosis</brief_title>
  <acronym>FAIR</acronym>
  <official_title>Femoral Artery In-Stent Restenosis (FAIR) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of recurrent-restenosis rates 6 months after angioplasty of in-stent restenoses or
      in-stent reocclusions in the superficial femoral artery (SFA) using either a standard balloon
      (Admiral Xtreme, Invatec) or a paclitaxel-eluting balloon (In.Pact™ Admiral, Invatec).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duplex-ultrasound determined recurrent restenosis in the superficial femoral artery (SFA)</measure>
    <time_frame>6 month</time_frame>
    <description>Binary restenosis rate by Duplex-ultrasound &gt;= 50% measured as proximal peak velocity ratio PVR[prox] &gt;= 2.4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent restenosis within the stent at 12 month</measure>
    <time_frame>12 month</time_frame>
    <description>Recurrent restenosis &gt;= 50% measured as proximal peak velocity ratio PVR[prox] &gt;= 2.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically driven target lesion revascularization (TLR) at 6 and 12 month</measure>
    <time_frame>6 and 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent stenosis &gt;= 70% within the stent at 6 and 12 month</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Recurrent restenosis &gt;= 70% measured as proximal peak velocity ratio PVR[prox] &gt;= 3.4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and hemodynamic parameters</measure>
    <time_frame>at 1, 6 and 12 month</time_frame>
    <description>Walking distance, ABI, Rutherford category</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary angiographic success rate</measure>
    <time_frame>12 month</time_frame>
    <description>Angiographic sucess: &lt;50% residual stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse vascular events (MAVE)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of &quot;bail-out&quot; stent-in-stent placement on 6-and 12-month end points</measure>
    <time_frame>6 and 12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>Standart balloon angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Admiral Xtreme, Invatec</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel-eluting balloon arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In.Pact Admiral, Invatec</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Admiral Xtreme</intervention_name>
    <description>For balloon angioplasty of in-stent restenosis in the superficial femoral artery</description>
    <arm_group_label>Standart balloon angioplasty</arm_group_label>
    <other_name>Admiral Xtreme, Invatec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>In.Pact Admiral</intervention_name>
    <description>For balloon angioplasty of in-stent restenosis in the superficial femoral artery</description>
    <arm_group_label>Paclitaxel-eluting balloon arm</arm_group_label>
    <other_name>In.Pact Admiral, Invatec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 21 years old.

          2. Patient must sign informed consent form.

          3. Patient must agree to participate in the study and comply with follow-up requirements.

          4. Clinically, all patients must be in Rutherford category 2 to 4.

             Angiographic Inclusion Criteria:

          5. Planned angioplasty of in-stent restenoses (degree of stenosis 70-100%) within the
             SFA. The target lesion must not extend beyond the stent margins. In cases of two or
             more stenotic regions within the stented segment, these are considered separate
             lesions if there is a nonstenotic or only mildly stenotic (&lt; 30%) segment of at least
             2 cm in length between them. Otherwise, they are considered a single lesion. In case
             of separate lesions, only the proximal lesion will be taken as the target lesion!

          6. The length of the in-stent lesion should be at least 1 cm and maximally 20 cm
             (measurement by radiopaque ruler).

          7. The degree of target lesion stenosis must be determined by pre-interventional duplex
             ultrasound.

          8. The target lesion region starts at the origin of the SFA and ends distally at the
             femoropopliteal crossover (crossing by SFA of medial rim of femur in the PA
             projection).

          9. Patency (&lt; 50% stenosis) of popliteal artery and at least 1 infragenicular artery.

        Exclusion Criteria:

        General:

          1. Patient is currently participating in another clinical trial.

          2. Pregnancy or pregnancy planned during study duration.

          3. Life expectancy less than 1 year.

          4. Co-morbidities preventing study participation.

          5. Severe coagulation disorders.

          6. Current treatment with anticoagulants other than aspirin, ticlopidine, clopidogrel or
             prasugrel.

          7. Active gastric ulcer or gastrointestinal bleeding.

          8. Thrombotic occlusion of the target vessel within previous 4 weeks.

          9. Treatment of target lesion with laser or atherectomy devices.

         10. Dialysis dependency.

         11. Manifest hyperthyreosis.

         12. Known allergy against contrast agent that cannot be adequately controlled by usual
             premedication.

         13. Known heparin intolerance.

         14. Known paclitaxel intolerance.

             Angiographic:

         15. Target lesion extends into the popliteal artery.

         16. Symptomatic untreated inflow lesion &gt; 50% in ipsilateral iliac arteries. Pretreatment
             of iliac stenoses is possible.

         17. SFA lesions &gt; 50% stenosis proximal and/or distal to the target lesion that require
             treatment.

         18. Target lesion extends beyond the stent margins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Krankenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Care Center Prof. Mathey, Prof. Schof Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thilo Tübler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Care Center Prof. Mathey, Prof. Schofer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Care Center Prof. Mathey, Prof. Schofer</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2011</study_first_submitted>
  <study_first_submitted_qc>February 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2011</study_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Standard balloon angioplasty</keyword>
  <keyword>POBA</keyword>
  <keyword>Angioplasty with paclitaxel-eluting balloon</keyword>
  <keyword>Superficial femoral artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

